Assessing the linkage between stress and immune function strengthened by this new collaboration.

I cannot overstate the importance of Dr. Calabrese joining the Inmedix Scientific Advisory Board.”

— Andrew J Holman MD, CEO, Inmedix

NORMANDY PARK, WA, USA, September 17, 2018 / — In its continuing effort to define immuno-autonomics affecting patients with autoimmune disease, Inmedix today announced the addition of Leonard H. Calabrese, DO, FACR, to its elite Scientific Advisory Board (SAB). Dr. Calabrese is Professor of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Vice Chairman of the Department of Rheumatic and Immunological Diseases, Co-director of the Center for Vasculitis Care and Research, and Director of the RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic in Cleveland, Ohio.

“I am excited to engage with Inmedix in their effort to advance the science of neuroimmunology for patients with immune-mediated inflammatory diseases,” said Dr. Calabrese.

On the Inmedix SAB, Dr. Calabrese joins two past-Presidents of the American College of Rheumatology, Michael Weinblatt MD (Harvard University) and James O’Dell MD (University of Nebraska), and other leading international rheumatologists, including Mark Genovese MD (Stanford University), Vibeke Strand MD (Stanford University), Edward Keystone MD (University of Toronto), Daniel Furst MD (University of Washington, University of Florence, Italy and UCLA), Robert Ettlinger MD, (WIRB), Ernest Choy MD (Cardiff University) and Peter Taylor MD PhD (University of Oxford).

Immuno-autonomics is the interface between the immune system and stress, modulated within the brain by the autonomic nervous system (ANS). Patients with autoimmune disease have long noted that stress significantly affects their disease activity and response to treatment. Dr. Calabrese is an internationally recognized leader in HIV/AIDS and hepatitis C research. He has also championed the importance of stress in the setting of an autoimmune disease and has promoted mitigating wellness strategies to reduce the adverse effect of stress on patients.

“I cannot overstate the importance of Dr. Calabrese joining the Inmedix Scientific Advisory Board,” said Andrew J Holman MD, Co-founder and CEO of Inmedix, Inc. and Clinical Associate Professor of Medicine at the University of Washington. “His leadership will be invaluable to guide immuno-autonomic research and explore potential applications to help patients with autoimmune diseases.”

About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.

Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd. are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress, modulated within the brain by the autonomic nervous system (ANS). The Inmedix ANS Neuroscan™ is leading applications of next-generation heart rate variability (HRV) as an informative diagnostic, therapeutic, digital health and health economic tool in autoimmune disease. ANS profile may be the most overlooked element of personalized, precision medicine. Beginning with rheumatoid arthritis (RA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and ankylosing spondylitis (AS) in adults, the company hopes to enhance current therapeutic outcomes through complimentary optimization of individual ANS profile.

Rae Marie Gleason
Education Program Director, Inmedix, Inc.
email us here


Powered by WPeMatico